Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. News about PROCEPT BioRobotics frequently centers on its AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy for benign prostatic hyperplasia (BPH) and are being evaluated in clinical studies for localized prostate cancer.
Investors and clinicians following PRCT news can expect regular updates on quarterly financial results, revenue guidance, and operating metrics such as U.S. system placements, handpiece and consumable revenue, and international performance. The company issues detailed earnings press releases and hosts conference calls and webcasts to discuss its results and outlook.
Company news also covers clinical and regulatory milestones. Examples include progress in the WATER IV Prostate Cancer Trial, which compares Aquablation therapy with radical prostatectomy, and developments related to reimbursement, such as the assignment of a Category I CPT code for Aquablation therapy in the Medicare Proposed Physician Fee Schedule. These items provide insight into how the therapy is being integrated into clinical practice and payment systems.
Additional PRCT headlines highlight participation in healthcare and investor conferences, executive leadership updates, and commentary on the growing body of peer-reviewed publications supporting Aquablation therapy. For anyone tracking the evolution of robotic urology treatments, the PROCEPT BioRobotics news feed offers a centralized view of financial performance, clinical research, reimbursement changes, and corporate events related to Aquablation therapy and the company’s robotic platforms.
PROCEPT BioRobotics presented long-term real-world data at the 2024 AUA Annual Meeting demonstrating the sustained benefits of Aquablation therapy for men with benign prostatic hyperplasia (BPH). The data showcased the efficacy of Aquablation therapy in treating BPH, emphasizing safety, durability, and positive outcomes such as improved International Prostate Symptom Score (IPSS) and increased peak urinary flow rate (Qmax). The results from various studies highlighted the potential for Aquablation therapy to become the new standard of care in BPH management.
PROCEPT BioRobotics reported total revenue of $44.5 million for the first quarter of 2024, marking an 83% increase from the previous year. The company's U.S. revenue saw significant growth across various segments, with handpiece and consumables revenue increasing by 101%. The company sold 38 U.S. robotic systems during the quarter and increased its international revenue by 65% compared to the prior year period. PROCEPT adjusted its fiscal year 2024 total revenue guidance to $213.5 million, showcasing a strong start to the year and optimistic growth projections.
PROCEPT BioRobotics presented a late-breaking post-market survey at the Japanese Urological Association Annual Meeting on positive Aquablation therapy outcomes for men in Japan with lower urinary tract symptoms due to benign prostatic hyperplasia. The data showcased the safety and effectiveness of Aquablation therapy in treating men with BPH, highlighting reproducible results and supporting a paradigm shift in the surgical treatment of the condition.
Key highlights from the data include treating 103 men with mean age and baseline IPSS of 71 ± 7 and 18 ± 9, respectively, with a mean prostate volume of 82 ml. The data showed significant improvements in IPSS and quality-of-life scores, with no reports of pad-use incontinence or serious device-related adverse events. The results demonstrate the exceptional safety and efficacy of Aquablation therapy in Japanese men with BPH.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.